Pharos IBio Co Ltd
388870
Company Profile
Business description
Pharos IBio Co Ltd is a company specializing in new drug development that develops treatments for rare and intractable diseases. It utilizes a new drug development platform based on big data and AI technology. Its product candidate comprises PHI-101-AML, a treatment drug for refractory/relapsed acute myeloid leukemia; PHI-101-OC developed for platinum-resistant/refractory ovarian cancer patients; PHI-101-TNBC is being developed as a drug to treat metastatic triple-negative breast cancer (TNBC); PHI-201; PHI-301; and PHI-501.
Contact
427beon-gil, Dongan-gu
1407 and 1408, 38, Heungan-daero, Seongji Star With
Gyeonggi-do, Gwanyang-dong
Anyang-si
KORT: +82 313456170
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
34
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,813.70 | 100.20 | -1.27% |
| CAC 40 | 7,126.02 | 263.00 | 3.83% |
| DAX 40 | 20,562.73 | 891.85 | 4.53% |
| Dow JONES (US) | 39,593.66 | 1,948.07 | 5.17% |
| FTSE 100 | 7,913.25 | 141.73 | -1.76% |
| HKSE | 20,782.99 | 101.21 | 0.49% |
| NASDAQ | 16,387.31 | 1,119.40 | 7.33% |
| Nikkei 225 | 33,240.21 | 1,368.79 | -3.96% |
| NZX 50 Index | 12,049.14 | 152.29 | -1.25% |
| S&P 500 | 5,268.05 | 188.85 | -3.46% |
| S&P/ASX 200 | 7,607.90 | 101.70 | -1.32% |
| SSE Composite Index | 3,227.65 | 4.02 | 0.12% |